EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study

Janet Brown iD, Margaret A Paggiosi iD, Emma Rathbone, Walter Gregory iD, Gian Bertelli, Omar Din, Eugene McCloskey, David Dodwell, David Cameron, Richard Eastell iD, Robert Coleman

Journal of Bone and Mineral Research · 2024

DOI: 10.1093/jbmr/zjad006 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Bone and Mineral Research, 2024. Verfasst von Janet Brown und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Medicine, University of Sheffield, Sheffield, S10 2SJ, United Kingdom. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novartis Pharmaceuticals, National Cancer Research Network, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjuvant bisphosphonates are often recommended in postmenopausal women with early breast cancer at intermediate-to-high risk of disease recurrence, but the magnitude and duration of their effects on bone mineral density (BMD) and bone turnover markers (BTMs) are not well described. We evaluated the impact of adjuvant zoledronate on areal BMD and BTMs in a sub-group of patients who had completed the large 5-yr randomized Adjuvant Zoledronic Acid to Reduce Recurrence (AZURE) trial. About 224 women (recurrence free) who had completed the AZURE trial within the previous 3 mo were recruited from 20 UK AZURE trial sites. One hundred twenty had previously been randomized to zoledronate (19 doses of 4 mg over 5 yr) and 104 to the control arm. BMD and BTMs were assessed at sub-study entry, 6 (BTMs only), 12, 24, and 60 mo following the completion of AZURE. As expected, mean BMD, T-scores, and Z-scores at sub-study entry were higher in the zoledronate vs the control arm. At the lumbar spine, the mean (SD) standardized BMD (sBMD) was 1123 (201) and 985 (182) mg/cm2 in the zoledronate and control arms, respectively (P < .0001). The baseline differences in sBMD persisted at all assessed skeletal sites and throughout the 5-yr follow-up period. In patients completing zoledronate treatment, BTMs were significantly lower than those in the control arm (α- and β-urinary C-telopeptide of type-I collagen, both P < .00001; serum intact pro-collagen I N-propeptide, P < .00001 and serum tartrate-resistant acid phosphatase 5b, P = .0001). Some offset of bone turnover inhibition occurred in the 12 mo following the completion of zoledronate treatment. Thereafter, during the 60 mo of follow-up, all BTMs remained suppressed in the zoledronate arm relative to the control arm. In conclusion, in addition to the known anti-cancer benefits of adjuvant zoledronate, there are likely to be positive, lasting benefits in BMD and bone turnover.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsBreast NeoplasmsHumansFemaleDiphosphonatesZoledronic AcidBone DensityImidazolesNeoplasm Recurrence, LocalLumbar VertebraeBone RemodelingCollagen

Stichwörter der Autor:innen

AZURE trialadjuvant bisphosphonatesbone mineral densitybone turnover markersbreast cancer

Substanzen

DiphosphonatesZoledronic AcidBone Density Conservation AgentsImidazolesCollagen

Autor:innen und Institutionen

  • Division of Clinical Medicine, University of Sheffield, Sheffield, S10 2SJ, United Kingdom.
  • Sheffield Teaching Hospitals NHS Foundation Trust, Glossop Rd, Sheffield, S10 2JF, United Kingdom.
  • Huddersfield Royal Infirmary, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, HD3 3EA, United Kingdom.
  • Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT, United Kingdom.
  • Sussex Cancer Centre, University Hospitals Sussex NHS Trust, Bristol Gate, Brighton, BN2 5BD, United Kingdom.
  • Leeds General Infirmary, LeedsTeaching Hospitals NHS Trust, Leeds, LS1 3EX, United Kingdom.

ORCID-Profile: Janet Brown, Margaret A Paggiosi, Walter Gregory, Richard Eastell

Förderung

  • Novartis Pharmaceuticals
  • National Cancer Research Network
  • National Institute for Health and Care Research

Zitieren

APA

Brown, J., Paggiosi, M. A., Rathbone, E., Gregory, W., Bertelli, G., Din, O., McCloskey, E., Dodwell, D., Cameron, D., Eastell, R., & Coleman, R. (2024). Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study. Journal of Bone and Mineral Research. https://doi.org/10.1093/jbmr/zjad006

Vancouver

Brown J, Paggiosi MA, Rathbone E, Gregory W, Bertelli G, Din O, et al. Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study. Journal of Bone and Mineral Research. 2024. doi:10.1093/jbmr/zjad006

BibTeX
@article{Brown2024,
  author = {Brown, Janet and Paggiosi, Margaret A and Rathbone, Emma and Gregory, Walter and Bertelli, Gian and Din, Omar and McCloskey, Eugene and Dodwell, David and Cameron, David and Eastell, Richard and Coleman, Robert},
  title = {Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study},
  journal = {Journal of Bone and Mineral Research},
  year = {2024},
  doi = {10.1093/jbmr/zjad006}
}
Kostenlos starten →